Shares of Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.25.
Several brokerages have commented on IAM. Citigroup began coverage on Iambic Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $22.00 price target for the company. Zacks Research initiated coverage on Iambic Therapeutics in a research report on Tuesday, November 10th. They issued a “hold” rating for the company. JPMorgan Chase & Co. began coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They issued an “overweight” rating and a $22.00 price objective on the stock. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Finally, Jefferies Financial Group started coverage on shares of Iambic Therapeutics in a report on Tuesday, November 10th. They issued a “buy” rating and a $35.00 price target for the company.
Check Out Our Latest Research Report on IAM
Iambic Therapeutics Stock Performance
NASDAQ IAM opened at $14.76 on Thursday. Iambic Therapeutics has a 52-week low of $9.60 and a 52-week high of $25.00.
Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($6.23) EPS for the quarter, missing the consensus estimate of ($0.33) by ($5.90). The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $42.50 million. On average, sell-side analysts expect that Iambic Therapeutics will post -1.79 EPS for the current fiscal year.
Insider Buying and Selling at Iambic Therapeutics
In other news, Director Evan Lockwood Rachlin purchased 718,750 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the acquisition, the director directly owned 2,588,248 shares of the company’s stock, valued at $41,411,968. The trade was a 38.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 22.90% of the stock is currently owned by company insiders.
About Iambic Therapeutics
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
See Also
- Five stocks we like better than Iambic Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
